4- Thursday Pharmacotherapy News – 19th August

1 – COVID-19 challenges and its therapeutics

• COVID-19, an infectious disease, has emerged as one of the leading causes of death worldwide, making it one of the severe public health issues in recent decades.
• nCoV, the novel SARS coronavirus that causes COVID-19, has brought together scientists in the quest for possible therapeutic and preventive measures.
• The development of new drugs to manage COVID-19 effectively is a challenging and time-consuming process, thus encouraging extensive investigation of drug repurposing and repositioning candidates.
• Several medications, including remdesivir, hydroxychloroquine, chloroquine, lopinavir, favipiravir, ribavirin, ritonavir, interferons, azithromycin, capivasertib and bevacizumab, are currently under clinical trials for COVID-19.
• This study aims to highlight the recent trends in COVID-19, relevant statistics, and clinical findings, as well as potential therapeutics, including in-line treatment methods, preventive measures, and vaccines to combat the prevalence of COVID-19.

Source: ScienceDirect

2 – Study Indicates Flu Shot May Protect Against Severe Effects of COVID-19

• The flu vaccine has the potential to provide vital protection against COVID-19, according to new research.
• The study, which analyzed de-identified patient records on a global scale, strongly suggests that the annual flu shot reduces the risks of stroke, sepsis, and deep vein thrombosis (DVT) in patients with COVID-19. Those with COVID-19 who have been vaccinated against the flu were also significantly less likely to visit the emergency department (ED) and be admitted to the intensive care unit (ICU), according to the study.
• The research team conducted the study using patient records from several countries.
• The results revealed that those who had not had the flu shot were significantly more likely to have been admitted to the ICU.

Source: Pharmacy Times

3 – Combination of Plinabulin and Docetaxel More Effective Than Docetaxel Alone in Certain Patients With NSCLC

• The combination of plinabulin and docetaxel increased overall survival (OS) in patients with second- and third-line non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) wild type compared to docetaxel alone, according to topline data from the DUBLIN-3 registrational trial.
• Plinabulin is a selective immunomodulating microtubule-binding agent (SIMBA), which is an antigen presenting cell (APC) inducer.
• According to the data, the combination also significantly improved overall response rate, progression-free survival, and 24- and 36-month OS rates, as well as a significant reduction in the incidence of grade 4 neutropenia.

Source: Pharmacy Times

4- Study: ADHD Medications Associated With Reduced Risk of Suicidality in Children With Significant Behavioral Symptoms

• New findings from the Lifespan Brain Institute (LiBl) of the Children’s Hospital of Philadelphia and the University of Pennsylvania found that attention-deficit hyperactivity disorder (ADHD) medications may lower the risk of suicide in children with hyperactivity, oppositional defiance, and other behavioral disorders.
• This information addresses a significant knowledge gap in childhood suicide risk and could enlighten suicide prevention strategies at this time, since suicide among children is on the rise.

Source: Pharmacy Times

5 – Erenumab Monotherapy Shows Sustained Long-Term Efficacy in Patients With Episodic Migraine

• In patients with episodic migraine who did not successfully respond to 2 to 4 prior preventive treatments, erenumab was found to have a sustained efficacy as a monotherapy treatment during a period of up to 64 weeks, according to results from the LIBERTY study.
• During the study, investigators enrolled 240 patients with episodic migraine who had previously completed the double-blind treatment trial phase (DBTP).
• In DBTP, patients received either a placebo or erenumab at 140 mg as a monotherapy administered through subcutaneous injections every 4 weeks.

Source: Pharmacy Times

6 – Continuous Glucose Monitoring Improves Outcomes for Patients With Type 2 Diabetes Using Only Basal Insulin

• Continuous glucose monitoring significantly decreased hgA1C levels for patients with poorly controlled type 2 diabetes compared to blood glucose meter monitoring, according to a study published in JAMA.
• Though the benefits of continuous glucose monitoring for patients with diabetes has been previously demonstrated, the investigators said that these benefits have only been well-established for patients with type 1 diabetes or patients with type 2 diabetes treated with multiple daily insulin injections.
• However, the current study is one of the first to demonstrate the benefits of continuous glucose monitoring for patients with type 2 diabetes only treated with basal insulin, a long-acting insulin designed to be injected once or twice daily.

Source: Pharmacy Times

• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2021 Pharmacotherapy Daily News (FNN) ?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2021 Pharmacotherapy Daily News (FNN), for a publication of E-News

Read & Download FNN Issue 8 of April 2020 FNN News